help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mullen, J. T.
Right arrow Articles by Tanabe, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mullen, J. T.
Right arrow Articles by Tanabe, K. K.
The Oncologist, Vol. 7, No. 2, 106-119, April 2002
© 2002 AlphaMed Press

Viral Oncolysis

John T. Mullena, Kenneth K. Tanabea,b

a Division of Surgical Oncology and b MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Kenneth K. Tanabe, M.D., Division of Surgical Oncology, Massachusetts General Hospital, Cox 626, 100 Blossom Street, Boston, Massachusetts 02114-2696, USA. Telephone: 617-724-3868; Fax: 617-724-3895; e-mail: ktanabe{at}partners.org

The concept of using replicating viruses as anticancer agents is not a new one, but the ability to genetically modify these viruses into increasingly potent and tumor-specific vectors is a recent phenomenon. As more is learned about the functions of viral gene products in controlling the mammalian cell cycle and in disabling cellular defense mechanisms, specific viral functions can be augmented or eliminated to enhance antineoplastic efficacy. In this article, general mechanisms by which oncolytic viruses achieve their antitumor efficacy and specificity are reviewed. The paradoxical roles of the immune response are addressed with respect to oncolytic viral therapy, as it, on one hand, impedes the spread of viral infection, and on the other, augments tumor cell destruction through the recruitment of T cells "vaccinated" against tumor antigens. The most commonly used oncolytic viruses are each reviewed in turn, including adenoviruses, herpes simplex viruses, vaccinia viruses, reoviruses, and Newcastle disease viruses. Special attention is focused on the unique biology of each of these viruses as well as the status of several of these mutants in clinical trials.

Key Words. Oncolysis • Replication-conditional viruses • Gene therapy • Clinical trials




This article has been cited by other articles:


Home page
Cancer Res.Home page
D. Kuruppu, A.-L. Brownell, A. Zhu, M. Yu, X. Wang, Y. Kulu, B. C. Fuchs, H. Kawasaki, and K. K. Tanabe
Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis
Cancer Res., April 1, 2007; 67(7): 3295 - 3300.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
Z. Fabian, C. M. Csatary, J. Szeberenyi, and L. K. Csatary
p53-Independent Endoplasmic Reticulum Stress-Mediated Cytotoxicity of a Newcastle Disease Virus Strain in Tumor Cell Lines
J. Virol., March 15, 2007; 81(6): 2817 - 2830.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. M. Stanford, J. W. Barrett, S. H. Nazarian, S. Werden, and G. McFadden
Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells
J. Virol., February 1, 2007; 81(3): 1251 - 1260.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
D. Cross and J. K. Burmester
Gene therapy for cancer treatment: past, present and future.
Clin. Med. Res., September 1, 2006; 4(3): 218 - 227.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
P. Rudd and G. Lemay
Correlation between interferon sensitivity of reovirus isolates and ability to discriminate between normal and Ras-transformed cells
J. Gen. Virol., May 1, 2005; 86(5): 1489 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
L. Barzon, M. Boscaro, and G. Palu
Endocrine Aspects of Cancer Gene Therapy
Endocr. Rev., February 1, 2004; 25(1): 1 - 44.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. R. Shafren, G. G. Au, T. Nguyen, N. G. Newcombe, E. S. Haley, L. Beagley, E. S. Johansson, P. Hersey, and R. D. Barry
Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21
Clin. Cancer Res., January 1, 2004; 10(1): 53 - 60.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2002 by AlphaMed Press.